At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
In Brief
A Phase 3 clinical trial evaluating Andecaliximab, Placebo, and 3 other interventions for Gastric Adenocarcinoma. Completed, enrolled 432 participants across 134 sites in 16 countries.
Detailed Summary
The primary objective of this study is to compare the efficacy of andecaliximab (GS-5745) versus placebo in combination with modified fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (OXA) (mFOLFOX6) as measured by overall survival.
Study Details
Timeline
Interventions
800 mg administered intravenously on Days 1 and 15 of each 28-day treatment cycle
Administered intravenously on Days 1 and 15 of each treatment cycle
Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle